L-dopa treatment duration versus Parkinson's disease progression: the dorsal-ventral divide

Mov Disord. 2013 Feb;28(2):120-1. doi: 10.1002/mds.25334. Epub 2013 Feb 7.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antiparkinson Agents / adverse effects*
  • Basal Ganglia / physiopathology*
  • Dopamine Agents / adverse effects*
  • Female
  • Humans
  • Male
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology*

Substances

  • Antiparkinson Agents
  • Dopamine Agents